Cellectar Biosciences Converts Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles
10 November 2015 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the Company), an
oncology-focused biotechnology company, today announces that it has
converted its previously filed provisional patent application for
Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles to
non-provisional US and International (PCT) patent applications.
These patent applications further protect PDCs developed with
Cellectar's proprietary phospholipid-ether delivery vehicle
conjugated with any existing or future cytotoxic agents, including
chemotherapeutics such as paclitaxel, for targeted delivery to
cancer cells and cancer stem cells.
Both composition of matter and methods of use are covered by
these patent applications and provide intellectual property
protection in the United States and up to 148 additional countries.
This protection extends through at least November, 2034 in the US
and key international markets.
"This patent protects all PDCs comprised of cytotoxic compounds,
including chemotherapeutics, and provides Cellectar and potential
partners with 20 years of product development and commercialization
runway in key markets," said Jim Caruso, president and CEO of
Cellectar. "This expanded protection supports the value-optimizing
potential of our CLR CTX chemotherapeutic program and we look
forward to sharing future advancements."
The Company recently provided a preclinical update on its CLR
CTX program, which included the identification of a lead paclitaxel
analog, CLR 1603, for advancement to in vivo studies. The objective
of the CLR CTX program is to develop PDC chemotherapeutics through
conjugation of the Company's delivery vehicle and non-targeted
anti-cancer agents to improve therapeutic indices and expand
potential indications through the targeted delivery of
chemotherapeutic payloads.
About Phospholipid Drug Conjugates (PDCs)
Cellectar's PDC platform has demonstrated highly selective
cancer targeting both preclinically in over 60 in vivo cancer
models, and subsequently confirmed clinically in over 10 cancer
types. The platform's payload diversity has been validated using
cytotoxic radioisotopes for cancer therapy; PET imaging isotopes
for cancer imaging; fluorophores for image-guided surgery, and now
the company plans to expand its payload portfolio to
chemotherapeutics with further preclinical study of paclitaxel and
other non-targeted anti-cancer agents with both in-house and
collaborative R&D efforts.
Cellectar's lead PDC is CLR 131. Its payload is iodine-131, a
proven cytotoxic radioisotope that is used primarily for thyroid
cancer treatment. The company initiated a disease-specific Phase 1
dose escalation study in patients with relapsed or refractory
multiple myeloma this past April, and has been granted orphan drug
designation. The company expects to evaluate cohort 1 and initiate
cohort 2 during the first half of 2016. The primary objective of
the study is to assess the safety and tolerability of CLR 131 in
this patient population with secondary objectives of establishing
the recommended Phase 2 dose and characterizing therapeutic
activity.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have
demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates
for cancer therapy and cancer diagnostic imaging. The company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 study in patients with
relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form
10-K/A for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
CONTACT: INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024